Archive

Tag Archives: mental-health

Healthcare assistants play an essential role in administering medicines in residential care. But safe administration is not the same as clinical oversight. Unless the system ensures that residents’ medicines are regularly reviewed, interactions are identified, adverse effects are investigated and professional advice is readily available, preventable harm can go unnoticed.

The distinction that matters

In care homes across the UK, medicines are frequently administered by healthcare assistants and other care staff who are not registered healthcare professionals. This arrangement is not inherently unsafe or inappropriate. Staff who have received suitable training, been assessed as competent and are working within clear procedures can administer prescribed medicines safely and effectively.

The problem arises when the delegation of administration is not matched by effective clinical oversight.

Giving a tablet according to a medication administration record is a different task from determining whether that tablet remains appropriate for a particular resident, whether it interacts with other prescribed medicines, or whether the resident is experiencing an adverse reaction. These activities require different knowledge, skills and professional responsibilities.

The fundamental question is not who physically gives the medicine, but who takes responsibility for ensuring that the complete medication regimen remains clinically appropriate and safe.

In a care system where GPs prescribe, pharmacies dispense and care assistants administer, responsibility can become fragmented. Each participant may perform their assigned task, yet gaps can remain between prescribing decisions, the administration of medicines, clinical monitoring and subsequent review.

For residents who are frail, living with dementia or taking multiple medicines, those gaps matter. They can mean that a harmful combination persists, a side effect goes unrecognised or an unnecessary medicine continues long after its original purpose has disappeared.

The answer is not to diminish the role of care assistants or insist that every routine dose must be administered by a nurse. It is to establish a system in which delegated administration is supported by clear accountability, accessible clinical expertise and reliable review of the resident’s treatment.

The evidence of medication errors

The risks associated with medicines management in care homes have been documented in published research for many years.

In 2009, Barber and colleagues published the Care Homes’ Use of Medicines Study (CHUMS), investigating medication errors among residents in UK care homes. The study examined 256 residents across 55 homes and found that 178 residents, or 69.5% of the sample, had experienced at least one medication error. Residents were taking an average of eight medicines.

The researchers identified contributing factors that included staff workload, interruptions during medication rounds, inadequate training, inaccurate records and communication failures between care homes, GP practices and pharmacies. They also highlighted weaknesses in overall responsibility for medicines safety.

These findings are important because they point beyond individual mistakes. A medication error may occur at the point of administration, but its underlying causes can lie elsewhere: an inaccurate prescription, a failure to communicate a change in treatment, inadequate monitoring or the absence of an effective process for reviewing the whole medication regimen.

Barber et al., Care Homes’ Use of Medicines Study, Quality and Safety in Health Care, 2009.

The figures must be interpreted in their historical context. They describe the residents and homes studied in 2009 and should not be presented as an estimate of the current national error rate. Nevertheless, the study remains an important examination of the organisational weaknesses that can undermine medicines safety.

A 2022 review published in The Pharmaceutical Journal, examining medication errors and inappropriate medicine use in UK care homes, also identified prescribing and administration errors as significant concerns. The literature discussed factors including polypharmacy, understaffing, dementia, swallowing difficulties and inadequate communication between prescribers, pharmacists and care staff. The authors highlighted the potential value of regular pharmacist-led medication reviews, staff education and improved reporting of medication errors.

Pepple and Boumechache, Errors and the inappropriate use of medicines in UK care homes, 2022.

Taken together, these publications support a clear conclusion: medicines safety depends on the reliability of the whole system, not simply on whether the person administering a dose follows the correct procedure.

Why correct administration does not guarantee safe treatment

Imagine a resident receiving medicines for hypertension, heart disease, diabetes, chronic pain and anxiety. Each medicine may have been prescribed for a legitimate reason. The resident’s care assistant administers each dose correctly and records it accurately.

Yet the resident begins to experience dizziness, increasing confusion and recurrent falls.

The administration records may reveal no error. The medicines may have been given at the prescribed times and in the prescribed doses. Nevertheless, the combined treatment may be contributing to the resident’s deterioration.

Several medicines can have additive effects on blood pressure, alertness or balance. Changes in kidney function can affect the handling of particular drugs. An illness, an episode of dehydration or a hospital admission can alter the balance between the benefits and risks of an established regimen. A medicine that was once appropriate may become unnecessary or harmful as the resident’s condition changes.

A care assistant may be the first person to notice that the resident is unusually drowsy or unsteady. That observation is clinically valuable and should trigger an appropriate response. But determining whether the symptoms represent an adverse drug reaction, an interaction, an excessive cumulative effect or an unrelated illness requires further assessment.

This is where the distinction between administration and oversight becomes critical.

Care assistants should not be expected to diagnose complex drug interactions or independently alter prescriptions. Equally, a system should not depend on them recognising every potential interaction or adverse effect before a qualified professional becomes involved.

Their responsibility is to administer medicines within their competence, observe the resident, document relevant information and escalate concerns. The clinical system must then ensure that those concerns can be assessed promptly and that treatment can be reconsidered when necessary.

Without this link, even a perfectly completed medication administration record can coexist with unsafe treatment.

Polypharmacy requires active clinical management

Polypharmacy is common among older people and is not automatically inappropriate. For residents with several chronic conditions, multiple medicines may be necessary to manage symptoms, prevent complications and maintain quality of life.

The problem is inappropriate or insufficiently reviewed polypharmacy: combinations that no longer provide sufficient benefit, create avoidable risks or continue without adequate consideration of the resident’s changing circumstances.

Potential concerns include:

  1. Interactions that increase the toxicity of one or more medicines.
  2. Combined sedative effects that contribute to falls, impaired alertness or confusion.
  3. Multiple medicines contributing to low blood pressure or an increased risk of bleeding.
  4. Adverse effects being mistaken for the progression of dementia or another underlying illness.
  5. Medicines continuing after their original indication has disappeared.
  6. A new medicine being prescribed to treat a symptom caused by another medicine, creating a prescribing cascade.

Identifying these problems requires more than checking the individual entries on a medication administration record. It requires consideration of the resident’s complete treatment, medical history, current symptoms, relevant investigations and personal priorities.

The Royal Pharmaceutical Society’s report, The Right Medicine: Improving Care in Care Homes (2016), provides a professional basis for strengthening this approach. It advocates a greater role for pharmacists in improving medicines management and working with care homes and other healthcare professionals.

Royal Pharmaceutical Society, The Right Medicine: Improving Care in Care Homes.

The significance of this approach is that clinical oversight should examine the whole regimen, rather than treating each prescription as an isolated decision. It should also establish whether intended benefits are being achieved, whether adverse effects are emerging and whether any medicines can be reduced or discontinued safely.

The guidance exists. The challenge is making it effective.

The National Institute for Health and Care Excellence (NICE) published Managing medicines in care homes (SC1) in 2014. Its recommendations address medicines-related responsibilities, staff competence, record keeping, medication errors, communication and medication reviews.

NICE expects care home providers to ensure that staff administering medicines are suitably trained and assessed as competent. It also recommends arrangements for medication reviews, including the involvement of a named health professional with appropriate clinical experience and knowledge of the resident. Reviews should take account of the resident’s needs and preferences and involve other professionals when appropriate.

Source: NICE, Managing medicines in care homes, recommendations.

These recommendations support the distinction at the heart of this article. Care staff can undertake the practical task of administering medicines, but this must operate within a wider framework of professional review, monitoring and accountability.

The existence of guidance does not establish that all homes follow it effectively. Nor does it prove that every home without an on-site registered nurse is unsafe. The relevant issue is whether each resident has access to appropriate clinical oversight, whether responsibilities are clearly assigned and whether the system responds effectively when risks emerge.

A written medicines policy is not enough if staff cannot obtain timely advice. A completed training record is not enough if nobody reviews the consequences of a complex medication regimen. A periodic medication review is not enough if significant changes in a resident’s condition are not recognised and acted upon between reviews.

The test should be whether the arrangements work in practice.

Why periodic reviews must be supported by ongoing oversight

Scheduled medication reviews are important, but they cannot anticipate every change in a resident’s health.

A hospital discharge may introduce new medicines, discontinue existing treatments or alter doses. An acute illness may affect kidney function, hydration or the resident’s ability to swallow. A new symptom may indicate an adverse reaction. A fall or a sudden change in mental state may require an urgent reassessment of treatment.

Care staff are often best placed to observe these changes because they provide day-to-day support. Their observations should feed into a clear clinical escalation process.

This does not mean that a doctor or pharmacist must be physically present whenever medicines are administered. Nor does it mean that every dose requires fresh clinical authorisation. It means that suitably qualified professionals must be responsible for reviewing treatment, be able to access relevant information and be available to advise when circumstances require reassessment.

NHS England’s structured medication review programme identifies care home residents as a group for whom structured reviews may be particularly important. The purpose is to consider the benefits and risks of treatment, particularly in people with complex or problematic polypharmacy.

NHS England, Structured medication reviews and medicines optimisation.

The policy direction is clear: medicines should be reviewed in the context of the individual resident, rather than continued indefinitely simply because they remain on a repeat prescription.

What is needed is a dependable connection between these reviews and everyday care. Staff must know how to report concerns, who will assess them and how resulting decisions will be communicated and implemented.

A model that separates responsibilities but joins up care

A safer approach would preserve the contribution of healthcare assistants while strengthening the clinical systems that support them.

1. Clear responsibility for the complete medication regimen

Every resident should have an identifiable arrangement for clinical medication review. Depending on the resident’s needs and local services, this may involve a suitably qualified pharmacist, GP or other appropriately trained prescriber.

The important requirement is that responsibilities are explicit, relevant information is available and someone has the authority and competence to assess the complete regimen.

Naming a professional on a care plan is not sufficient if that person cannot obtain the information needed to conduct a review or if recommendations are not followed through.

2. Comprehensive, risk-based medication reviews

Reviews should consider the indication for each medicine, potential interactions, cumulative side effects, relevant monitoring, the resident’s response to treatment and the possibility of reducing unnecessary medication.

They should also take account of the resident’s wishes and priorities. The objective is not to minimise the number of medicines at any cost, but to achieve the best balance of benefit and harm for the individual.

3. Timely clinical advice when concerns arise

Care staff need clear instructions on what to do when a resident develops new symptoms, refuses medicines, experiences a fall or shows a significant change in their condition.

There must be an effective route to professional assessment, with urgent concerns escalated appropriately. Where a medication discrepancy or possible adverse reaction is identified, staff need to know whom to contact and how the outcome will be recorded.

4. Training appropriate to the responsibilities of care staff

Training should cover safe administration, accurate documentation, the importance of following the current prescription and the recognition of warning signs. Staff should know the limits of their role and be confident about reporting concerns without being expected to make clinical decisions outside their competence.

Competence assessments and refresher training are necessary, but training should complement rather than substitute for professional oversight.

5. Monitoring and learning from medication incidents

Providers and their clinical partners should monitor errors, omissions, discrepancies, adverse reactions and delays in medication review. Near misses should also be reported and examined.

When incidents occur, investigations should consider not only the actions of the person administering the medicine but also the prescribing process, communication between organisations, staffing conditions, access to clinical advice and the adequacy of monitoring.

The objective should be to correct weaknesses in the system rather than reflexively attributing every failure to an individual member of staff.

6. Properly resourced clinical involvement

Pharmacist input, GP support and nursing expertise require time, agreed responsibilities and effective communication. Providers and commissioners must make suitable arrangements rather than relying on informal assistance or the goodwill of already overstretched professionals.

The appropriate level of involvement will vary with residents’ needs and the complexity of their treatment. However, the need for clinical oversight should not depend on whether a home happens to have a registered nurse permanently on site.

These changes would not remove all medication errors. They would, however, address the organisational conditions that can allow prescribing problems, adverse effects and medication discrepancies to persist undetected.

Accountability must extend beyond the person administering the medicine

When a medication error occurs, the most visible event may be an incorrect dose, an omitted tablet or a missing signature on a medication administration record.

Those matters require investigation. But a complete investigation must also ask whether the prescription was appropriate, whether the records were accurate, whether changes in treatment were communicated, whether monitoring was undertaken and whether staff could obtain clinical advice when necessary.

A care assistant may be responsible for following the procedures and instructions applicable to their role. They should not, however, become the default point of accountability for weaknesses that originate elsewhere in the system.

Responsibility must follow professional roles and actual control over decisions.

Prescribers are responsible for their prescribing decisions. Pharmacists contribute medicines expertise. Registered nurses, where involved, have responsibilities appropriate to their roles. Care assistants must work within their competence and report concerns. Care providers must maintain safe systems and ensure staff have the necessary training, information and support. Commissioners and healthcare services must establish workable arrangements for clinical input.

The Care Quality Commission’s medicines-management guidance reinforces the importance of safe systems for prescribing, handling and administering medicines.

CQC, guidance on medicines management and learning from safety incidents.

The central principle is straightforward: a system should not rely on every individual performing their task perfectly to compensate for gaps in the organisation of care. It should include safeguards that can identify problems, escalate concerns and correct mistakes before they cause harm.

The resident must remain at the centre

Medication safety is not simply a matter of compliance with procedures. It is about protecting people whose health, independence and quality of life may be profoundly affected by the medicines they receive.

A resident living with dementia may be unable to describe dizziness, nausea or increasing confusion. Someone with swallowing difficulties may struggle to take medicines as prescribed. A frail resident taking several medicines may be unable to recognise that increasing tiredness or unsteadiness could be treatment-related.

These people depend on care staff to notice changes and on clinical professionals to interpret those observations and act appropriately.

They also deserve to be involved in decisions about their treatment to the extent that they are able, with appropriate support where needed. A medication review should not be a purely administrative exercise between professionals. It should consider what matters to the resident, which symptoms are troubling them and whether the treatment continues to serve their interests.

Effective oversight therefore protects not only against medication errors but also against unnecessary treatment, avoidable side effects and the continuation of medicines that no longer provide sufficient benefit.

Conclusion: strengthen oversight, not blame care assistants

The evidence from UK care home research, together with guidance from NICE, the Royal Pharmaceutical Society and NHS England, supports the need for better-organised medicines management, clear professional responsibilities and structured clinical review.

The solution is not to prohibit appropriately trained healthcare assistants from administering medicines. Delegated administration can be a legitimate and effective part of residential care. The solution is to ensure that delegation never becomes a substitute for clinical oversight.

Administering a medicine correctly does not establish that the medicine is appropriate, that its combination with other treatments is safe or that its effects are being monitored adequately.

Every care home should be able to explain who is responsible for reviewing each resident’s medication regimen, how potentially harmful interactions and adverse effects are identified, how changes in the resident’s condition trigger reassessment and how quickly qualified clinical advice can be obtained.

It should also be possible to demonstrate that medication reviews lead to action, that incidents are investigated and that recurring problems result in improvements to the system.

If these safeguards are absent or ineffective, the problem is not simply a lack of individual training. It is a failure to connect the administration of medicines with the clinical expertise required to manage their risks.

Healthcare assistants should be supported to carry out their responsibilities safely and confidently. Residents, meanwhile, should be entitled to expect that the medicines they receive are not only administered correctly but also prescribed appropriately, reviewed regularly and monitored with the seriousness their health requires.

The objective must be a system in which responsibility for administering medicines is delegated appropriately, but responsibility for clinical oversight is never left ambiguous.

Principal references

  1. Barber, N. et al. (2009). Care Homes’ Use of Medicines Study (CHUMS). Full paper .
  2. Pepple and Boumechache (2022). Errors and the inappropriate use of medicinesin UK care homes. The Pharmaceutical Journal .
  3. Royal Pharmaceutical Society (2016). The Right Medicine: Improving Carein Care Homes. Report .
  4. NICE (2014). Managing medicines in care homes (SC1). Recommendations .
  5. NHS England. Structured medication reviews and medicines optimisation. Programme guidance .
  6. Care Quality Commission. Medicines management: learning from safetyincidents. Guidance .

Editorial note: The article is framed primarily around England because the cited NICE and CQC guidance applies there. Before publication as a UK-wide policy critique, the regulatory position and equivalent guidance in Scotland, Wales and Northern Ireland should be checked separately. The research statistics are attributed to the original studies rather than presented as current national estimates.

Psychiatric diagnoses are often made from patterns of symptoms, behaviour, history and clinical observation. Those tools are important—but when a diagnosis is questionable, atypical, unusually severe, treatment-resistant or accompanied by cognitive or neurological changes, they should not necessarily be the end of the investigation.

A questionable psychiatric diagnosis should trigger a serious search for neurological, cognitive, metabolic and endocrine explanations.

This is not an argument that psychiatric illness is “not real,” nor that every person with depression, psychosis, bipolar disorder or another psychiatric condition needs an enormous battery of tests. It is an argument for diagnostic humility: before permanently attributing unexplained changes in behaviour, personality, cognition or perception to a psychiatric disorder, clinicians should ask whether the brain and the body’s underlying physiology have been adequately investigated.

Start with objective cognitive testing

A detailed neuropsychological or neurological cognitive assessment can provide information that a conventional psychiatric interview may miss.

Memory, attention, processing speed, language, executive functioning, visuospatial abilities and working memory can be measured systematically. Patterns of impairment may point toward neurological disease, acquired brain injury, neurodegenerative processes or other conditions that can present with apparently psychiatric symptoms.

This is particularly important when someone reports a significant change from their previous cognitive functioning. The question should not simply be, “Does this person meet the criteria for a psychiatric disorder?” It should also be, “What has happened to this person’s brain function?”

Modern neuropsychiatric assessment explicitly recognises the importance of cognitive, neurological and laboratory information in understanding difficult presentations. 

MRI should not be dismissed when the presentation is unusual

When there is a credible possibility of neurological disease or brain injury, high-quality brain MRI deserves consideration.

MRI is generally more informative than CT for many structural brain abnormalities and provides better visualisation of grey and white matter and certain deeper brain structures. Neuropsychiatric references identify circumstances such as new-onset psychosis, cognitive decline, new personality change, seizures, traumatic brain injury and treatment-refractory presentations as situations in which structural imaging may warrant consideration.

The point is not that an MRI will automatically reveal the cause. It often will not. Nor should the phrase “high-resolution MRI” become a promise that subtle psychiatric symptoms can be explained by a scan.

The point is simpler: if neurological damage or disease is genuinely in the differential diagnosis, it should be investigated rather than assumed away. NICE material on first-episode psychosis likewise recognises neurological examination and targeted laboratory and EEG investigation, with MRI or CT considered when an organic cause is suspected.

EEG deserves consideration when electrical brain dysfunction is plausible

Some neurological disorders can produce behavioural, perceptual or cognitive symptoms that can be mistaken for psychiatric illness.

Seizure disorders are an obvious example. EEG is particularly relevant where there are episodes that are sudden, stereotyped, episodic or otherwise suggestive of abnormal electrical activity. Psychiatric assessment guidance notes that continuous or ambulatory EEG can sometimes be necessary to document abnormal activity when ordinary testing does not capture an event. 

That is why, where the clinical history makes intermittent electrical dysfunction plausible, a normal short routine EEG should not automatically end the neurological investigation.

In selected cases, prolonged ambulatory or video EEG, including a 48-hour study where clinically justified may provide substantially more opportunity to capture abnormalities than a brief recording.

But this distinction matters: a 48-hour EEG should be clinically indicated, not imposed indiscriminately on every psychiatric patient. Current psychiatric guidance generally describes EEG as an investigation to use when neurological history or examination raises the possibility of a seizure disorder or other neurological process. 

Endocrine and metabolic causes should be taken seriously

The brain does not operate independently of the rest of the body.

Thyroid dysfunction, metabolic abnormalities and other systemic illnesses can produce changes in mood, cognition, energy, sleep, behaviour and mental state. Consequently, laboratory investigation belongs in the differential diagnosis of unexplained psychiatric and cognitive presentations.

There is already recognition within psychiatric practice that physical and laboratory assessment is an important component of diagnosis and management. Standard investigations can include thyroid function and metabolic testing, with additional testing guided by the individual’s presentation. The principle should therefore be:

Do not diagnose the mind while ignoring the body.

Where symptoms suggest an endocrine disorder, the appropriate endocrine investigation should be pursued rather than assuming that psychiatric symptoms are necessarily primary.

This is not “psychiatry versus neurology”

The false choice is between saying that somebody has a psychiatric illness and saying that they have a neurological illness. Sometimes the answer is both. Sometimes neither initial diagnosis is correct.

A person can have a psychiatric disorder and a neurological disorder. Brain injury can coexist with depression. Epilepsy can coexist with anxiety. Endocrine disease can produce psychiatric symptoms. Medication, substances, sleep disorders and systemic illness can complicate an otherwise genuine psychiatric condition.

Neuropsychiatry exists precisely because the boundary between neurological and psychiatric presentations is not as clean as diagnostic labels can sometimes imply. The professional literature explicitly advocates an integrated approach rather than a rigid division between “psychiatric” and “neurological” disease.

The standard should be diagnostic confidence—not diagnostic convenience

The strongest case is not for testing everyone. It is for testing appropriately when the diagnosis does not adequately explain the person in front of you.

Red flags might include:

  • a sudden or unusually late onset of psychiatric symptoms;
  • substantial or unexplained cognitive decline;
  • new personality or behavioural change;
  • episodes suggesting seizures or altered consciousness;
  • focal neurological symptoms or abnormal neurological findings;
  • a history of significant head injury;
  • an unusually atypical clinical presentation;
  • rapid deterioration;
  • unexpected treatment resistance; or
  • a substantial discrepancy between the psychiatric diagnosis and the person’s observed cognitive or neurological functioning.

These are precisely the sorts of circumstances in which psychiatric literature recommends considering additional medical or neurological evaluation. 

A more rigorous standard

When a psychiatric diagnosis is questionable, the appropriate response should not be to simply repeat the same psychiatric assessment until the original diagnosis appears more convincing.

It should be to expand the differential diagnosis. That may mean comprehensive cognitive testing, neurological examination, appropriate blood and endocrine investigations, high-quality brain MRI, and, when the history warrants it prolonged EEG monitoring such as a 48-hour ambulatory study.

None of these tests is infallible. None should be treated as a magical machine capable of proving or disproving a psychiatric diagnosis. And indiscriminate testing can create false positives, unnecessary anxiety and inappropriate treatment.

But the opposite error can be far more consequential: mistaking an unexplained neurological, cognitive or physiological disorder for a purely psychiatric one and never looking for anything else.

A psychiatric label should be a clinical hypothesis supported by evidence—not a reason to stop investigating.

When the diagnosis is questionable, the brain deserves to be examined, cognition deserves to be measured, electrical activity deserves to be considered, and the body’s physiology deserves to be investigated.

Good psychiatry should not fear neurological investigation. It should demand it when the clinical picture warrants it.

This is a drug well known to us for terrible adverse reactions – severe restlessness and Akathisia, not to mention excessive expenditure on shopping.. Once again it is prescribed off- label to counteract the effects of hyperprolactinaemia caused by another, despite substantial physical health decline and metabolic issues. This drug should not be accepted as any substitute for essential pathophysiological referrals and tests when there is overwhelming evidence in terms of need. I have highlighted the very important point on appropriateness. I will also highlight applicable issues below

The use of adjunctive aripiprazole to treat antipsychotic-induced hyperprolactinaemia has become an increasingly accepted off-label strategy within psychiatric practice. Randomised trials and systematic reviews demonstrate that low-dose aripiprazole can reduce serum prolactin concentrations in many patients receiving prolactin-raising antipsychotics. Yet clinical efficacy alone does not determine whether prescribing is appropriate.

Where treatment is off-label, the patient remains prescribed a long-acting depot antipsychotic, and there is evidence of multiple endocrine or metabolic abnormalities, the clinician’s responsibilities extend well beyond correcting a biochemical abnormality. The decision engages principles of clinical governance, informed consent, multidisciplinary care and, ultimately, the legal standard of care.

The medico-legal question is therefore not simply whether aripiprazole lowers prolactin. It is whether introducing a second dopamine-modulating medicine represents a reasonable, proportionate and defensible clinical response in the individual patient.

Off-Label Prescribing and the GMC: Professional Responsibilities

The General Medical Council’s Good practice in prescribing and managing medicines and devices recognises that prescribing outside a medicine’s licence may be appropriate. However, the guidance also makes clear that such prescribing carries enhanced professional responsibilities.

The prescriber should be satisfied that:

  • sufficient evidence or clinical experience supports the proposed treatment;
  • licensed alternatives have been properly considered;
  • the anticipated benefits outweigh foreseeable risks;
  • the patient is informed that treatment is being used outside its licensed indication where discussion is practicable;
  • material risks and reasonable alternatives are discussed;
  • the clinical reasoning is documented; and
  • appropriate monitoring arrangements are established.

These obligations become particularly important when the additional medication is not treating the primary psychiatric illness but is instead intended to mitigate an adverse effect of another prescribed psychotropic medicine.

NICE and the Royal College of Psychiatrists: Treat the Whole Patient

NICE guidance on psychosis, schizophrenia and medicines optimisation consistently promotes careful review of antipsychotic adverse effects rather than reflexively adding further medication. Hyperprolactinaemia should prompt reassessment of the overall treatment strategy, consideration of dose reduction where feasible, or switching to a prolactin-sparing antipsychotic if clinically appropriate.

Similarly, the Royal College of Psychiatrists has repeatedly emphasised that in cases of people with severe mental illness experience disproportionate rates of obesity, diabetes, cardiovascular disease, endocrine dysfunction and premature mortality, the College advocates parity of esteem between physical and mental healthcare, requiring psychiatrists to investigate physical illness with the same rigour expected in any other medical specialty.

Persistent hyperprolactinaemia accompanied by type 2 diabetes mellitus, obesity, hypogonadism, osteoporosis or other endocrine abnormalities should therefore trigger consideration of broader endocrine pathology rather than being viewed solely as a medication side effect.

Depot Antipsychotics Create a Higher-Risk Pharmacological Environment

The addition of aripiprazole is particularly complex where the patient remains prescribed depot antipsychotic injections.

Depot preparations cannot be rapidly withdrawn if clinically significant adverse effects develop. Dopamine receptor blockade continues for weeks after administration, substantially reducing therapeutic flexibility.

If adjunctive aripiprazole precipitates akathisia, agitation, insomnia or behavioural deterioration, clinicians cannot immediately remove the underlying pharmacological interaction. Consequently, the threshold for introducing additional dopamine-modulating medication should arguably be higher than in patients treated solely with oral antipsychotics.

Akathisia Is Not a Minor Adverse Effect

Aripiprazole is generally well tolerated, but akathisia remains one of its most clinically significant adverse effects.

Patients frequently describe overwhelming inner restlessness, profound anxiety, inability to remain still, agitation and severe psychological distress. These symptoms can be mistaken for worsening psychosis, anxiety disorders or behavioural disturbance, potentially resulting in further inappropriate prescribing.

The literature has also associated severe untreated akathisia with treatment discontinuation, self-harm and suicidal ideation in some patients.

Where aripiprazole has been prescribed solely to lower prolactin concentrations, the emergence of akathisia fundamentally alters the balance between therapeutic benefit and clinical risk.

Appropriate management should include urgent clinical review, consideration of dose reduction or discontinuation, reassessment of the antipsychotic regimen, symptomatic treatment where indicated, and close follow-up until symptoms resolve.

Multiple Endocrine Abnormalities Should Prompt Endocrinology Referral

The presence of hyperprolactinaemia together with type 2 diabetes mellitus or other endocrine abnormalities should prompt clinicians to ask a broader diagnostic question.

Is the patient experiencing a medication side effect alone, or does the presentation reflect wider endocrine disease requiring specialist investigation?

Potential differential diagnoses include pituitary pathology, hypogonadism, thyroid disease, adrenal disorders, metabolic syndrome and osteoporosis.

Adding aripiprazole may improve one biochemical parameter while delaying diagnosis of another clinically significant disorder.

Referral to a consultant endocrinologist should therefore be strongly considered where endocrine dysfunction extends beyond isolated hyperprolactinaemia, where symptoms remain unexplained, or where long-term complications require specialist assessment.

The Legal Framework: From Bolam to Montgomery

The legal analysis of these prescribing decisions has evolved significantly over recent decades.

Bolam v Friern Hospital Management Committee [1957]

The Bolam principle established that a clinician is not negligent simply because another clinician would have acted differently, provided the decision accords with a responsible body of professional opinion.

Historically, this afforded considerable protection to prescribing decisions supported by accepted clinical practice.

However, modern medical negligence law has moved well beyond Bolam alone.

Bolitho v City and Hackney Health Authority [1998]

The House of Lords refined the Bolam principle by holding that professional opinion itself must withstand logical analysis.

Courts are not obliged to accept expert evidence merely because other clinicians support it. The opinion must demonstrate coherent reasoning and appropriately balance risks against benefits.

In practical terms, this means that merely stating “adjunctive aripiprazole is accepted practice” may be insufficient if inadequate consideration was given to endocrine disease, alternative treatment options, foreseeable adverse effects or the patient’s individual circumstances.

Montgomery v Lanarkshire Health Board [2015]

The Supreme Court fundamentally reshaped informed consent.

Clinicians are now under a legal duty to ensure that patients are informed of:

  • material risks associated with proposed treatment;
  • reasonable alternative treatment options; and
  • the option of declining treatment altogether where appropriate.

A risk is material if a reasonable person in the patient’s position would likely attach significance to it, or if the clinician knows, or should reasonably know that the particular patient would likely consider it significant.

Applied to adjunctive aripiprazole, this means patients should ordinarily be informed about:

  • the off-label nature of treatment;
  • the possibility of akathisia, agitation and insomnia;
  • the possibility that treatment may not adequately resolve symptoms;
  • alternatives such as dose reduction, switching antipsychotics where clinically feasible, observation, or referral for endocrine assessment;
  • the uncertainties associated with adding another psychotropic medicine.

Failure to discuss these matters may expose clinicians to criticism even where prescribing itself was pharmacologically reasonable.

Documentation: The Clinician’s Strongest Defence

In medico-legal practice, contemporaneous documentation frequently determines whether a prescribing decision can be defended.

The medical record should clearly demonstrate:

  • why adjunctive aripiprazole was preferred over alternative strategies;
  • evidence supporting off-label prescribing;
  • informed consent discussions;
  • endocrine and metabolic assessment;
  • monitoring plans;
  • review arrangements;
  • contingency planning should adverse effects emerge.

Documentation should reflect a process of clinical reasoning rather than simply recording a prescribing decision.

Conclusion

Adjunctive aripiprazole remains a legitimate therapeutic option for selected patients with antipsychotic-induced hyperprolactinaemia. However, legitimacy does not eliminate professional responsibility.

Current GMC guidance, NICE recommendations and Royal College of Psychiatrists policy all point towards careful assessment, shared decision-making, systematic physical health monitoring and multidisciplinary management.

The legal authorities of Bolam, Bolitho and Montgomery reinforce these professional duties by requiring that prescribing decisions are supported by logical clinical reasoning, informed by responsible practice, and accompanied by meaningful patient involvement.

Where a patient receiving depot antipsychotic treatment develops persistent hyperprolactinaemia alongside diabetes mellitus or other endocrine abnormalities, the question should not simply be how to suppress prolactin. The more important question is whether the patient requires comprehensive endocrine investigation before additional psychotropic medication is introduced.

In many such cases, early referral to a consultant endocrinologist, combined with a multidisciplinary review of the antipsychotic regimen, is likely to represent the most clinically robust and the most legally defensible course of action.

It is extremely concerning that this drug is viewed by some psychiatrists to be an acceptable substitute for proper referral to see a Specialist Endocrinologist, especially when this drug, tried before had adversely affected behaviour and metabolism being a poor/non metaboliser ignored. This, combined with Clopixol Depot is hardly a suitable substitute for proper referrals in relation to physical healthcare. My blog “Outdated Practices” spells the need for rigorous care in terms of treatment which is what Precision Psychiatry is all about – patients under the MH deserve the very best of care yet this is not happening in the UK. Precision Psychiatry therefore needs to be mandatory to ensure that when a patient is not responding to treatment and has underlying physical health issues, that specialist referral is made to an Endocrinologist, neurologist, immunologist. Something needs to be done about this very urgently to stop mental health patients from being harmed. I shall post further example of the known effects of Aripiprazole which I doubt was ever informed in the circumstances. It is only right that patients are properly informed.

https://revelationsuk.com/2025/10/29/outdated-practices/

Off-Label Aripiprazole for Antipsychotic-Induced Hyperprolactinaemia: Clinical Judgement, Endocrine Risk and the Evolving Legal Standard of Care

The use of adjunctive aripiprazole to treat antipsychotic-induced hyperprolactinaemia has become an increasingly accepted off-label strategy within psychiatric practice. Randomised trials and systematic reviews demonstrate that low-dose aripiprazole can reduce serum prolactin concentrations in many patients receiving prolactin-raising antipsychotics. Yet clinical efficacy alone does not determine whether prescribing is appropriate.

Where treatment is off-label, the patient remains prescribed a long-acting depot antipsychotic, and there is evidence of multiple endocrine or metabolic abnormalities, the clinician’s responsibilities extend well beyond correcting a biochemical abnormality. The decision engages principles of clinical governance, informed consent, multidisciplinary care and, ultimately, the legal standard of care.

The medico-legal question is therefore not simply whether aripiprazole lowers prolactin. It is whether introducing a second dopamine-modulating medicine represents a reasonable, proportionate and defensible clinical response in the individual patient.

Off-Label Prescribing and the GMC: Professional Responsibilities

The General Medical Council’s Good practice in prescribing and managing medicines and devices recognises that prescribing outside a medicine’s licence may be appropriate. However, the guidance also makes clear that such prescribing carries enhanced professional responsibilities.

The prescriber should be satisfied that:

  • sufficient evidence or clinical experience supports the proposed treatment;
  • licensed alternatives have been properly considered;
  • the anticipated benefits outweigh foreseeable risks;
  • the patient is informed that treatment is being used outside its licensed indication where discussion is practicable;
  • material risks and reasonable alternatives are discussed;
  • the clinical reasoning is documented; and
  • appropriate monitoring arrangements are established.

These obligations become particularly important when the additional medication is not treating the primary psychiatric illness but is instead intended to mitigate an adverse effect of another prescribed psychotropic medicine.

NICE and the Royal College of Psychiatrists: Treat the Whole Patient

NICE guidance on psychosis, schizophrenia and medicines optimisation consistently promotes careful review of antipsychotic adverse effects rather than reflexively adding further medication. Hyperprolactinaemia should prompt reassessment of the overall treatment strategy, consideration of dose reduction where feasible, or switching to a prolactin-sparing antipsychotic if clinically appropriate.

Similarly, the Royal College of Psychiatrists has repeatedly emphasised that people with severe mental illness experience disproportionate rates of obesity, diabetes, cardiovascular disease, endocrine dysfunction and premature mortality. The College advocates parity of esteem between physical and mental healthcare, requiring psychiatrists to investigate physical illness with the same rigour expected in any other medical specialty.

Persistent hyperprolactinaemia accompanied by type 2 diabetes mellitus, obesity, hypogonadism, osteoporosis or other endocrine abnormalities should therefore trigger consideration of broader endocrine pathology rather than being viewed solely as a medication side effect.

Depot Antipsychotics Create a Higher-Risk Pharmacological Environment

The addition of aripiprazole is particularly complex where the patient remains prescribed depot antipsychotic injections.

Depot preparations cannot be rapidly withdrawn if clinically significant adverse effects develop. Dopamine receptor blockade continues for weeks after administration, substantially reducing therapeutic flexibility.

If adjunctive aripiprazole precipitates akathisia, agitation, insomnia or behavioural deterioration, clinicians cannot immediately remove the underlying pharmacological interaction. Consequently, the threshold for introducing additional dopamine-modulating medication should arguably be higher than in patients treated solely with oral antipsychotics.

Akathisia Is Not a Minor Adverse Effect

Aripiprazole is generally well tolerated, but akathisia remains one of its most clinically significant adverse effects.

Patients frequently describe overwhelming inner restlessness, profound anxiety, inability to remain still, agitation and severe psychological distress. These symptoms can be mistaken for worsening psychosis, anxiety disorders or behavioural disturbance, potentially resulting in further inappropriate prescribing.

The literature has also associated severe untreated akathisia with treatment discontinuation, self-harm and suicidal ideation in some patients.

Where aripiprazole has been prescribed solely to lower prolactin concentrations, the emergence of akathisia fundamentally alters the balance between therapeutic benefit and clinical risk.

Appropriate management should include urgent clinical review, consideration of dose reduction or discontinuation, reassessment of the antipsychotic regimen, symptomatic treatment where indicated, and close follow-up until symptoms resolve.

Multiple Endocrine Abnormalities Should Prompt Endocrinology Referral

The presence of hyperprolactinaemia together with type 2 diabetes mellitus or other endocrine abnormalities should prompt clinicians to ask a broader diagnostic question.

Is the patient experiencing a medication side effect alone, or does the presentation reflect wider endocrine disease requiring specialist investigation?

Potential differential diagnoses include pituitary pathology, hypogonadism, thyroid disease, adrenal disorders, metabolic syndrome and osteoporosis.

Adding aripiprazole may improve one biochemical parameter while delaying diagnosis of another clinically significant disorder.

Referral to a consultant endocrinologist should therefore be strongly considered where endocrine dysfunction extends beyond isolated hyperprolactinaemia, where symptoms remain unexplained, or where long-term complications require specialist assessment.

The Legal Framework: From Bolam to Montgomery

The legal analysis of these prescribing decisions has evolved significantly over recent decades.

Bolam v Friern Hospital Management Committee [1957]

The Bolam principle established that a clinician is not negligent simply because another clinician would have acted differently, provided the decision accords with a responsible body of professional opinion.

Historically, this afforded considerable protection to prescribing decisions supported by accepted clinical practice.

However, modern medical negligence law has moved well beyond Bolam alone.

Bolitho v City and Hackney Health Authority [1998]

The House of Lords refined the Bolam principle by holding that professional opinion itself must withstand logical analysis.

Courts are not obliged to accept expert evidence merely because other clinicians support it. The opinion must demonstrate coherent reasoning and appropriately balance risks against benefits.

In practical terms, this means that merely stating “adjunctive aripiprazole is accepted practice” may be insufficient if inadequate consideration was given to endocrine disease, alternative treatment options, foreseeable adverse effects or the patient’s individual circumstances.

Montgomery v Lanarkshire Health Board [2015]

The Supreme Court fundamentally reshaped informed consent.

Clinicians are now under a legal duty to ensure that patients are informed of:

  • material risks associated with proposed treatment;
  • reasonable alternative treatment options; and
  • the option of declining treatment altogether where appropriate.

A risk is material if a reasonable person in the patient’s position would likely attach significance to it, or if the clinician knows, or should reasonably know that the particular patient would likely consider it significant.

Applied to adjunctive aripiprazole, this means patients should ordinarily be informed about:

  • the off-label nature of treatment;
  • the possibility of akathisia, agitation and insomnia;
  • the possibility that treatment may not adequately resolve symptoms;
  • alternatives such as dose reduction, switching antipsychotics where clinically feasible, observation, or referral for endocrine assessment;
  • the uncertainties associated with adding another psychotropic medicine.

Failure to discuss these matters may expose clinicians to criticism even where prescribing itself was pharmacologically reasonable.

Documentation: The Clinician’s Strongest Defence

In medico-legal practice, contemporaneous documentation frequently determines whether a prescribing decision can be defended.

The medical record should clearly demonstrate:

  • why adjunctive aripiprazole was preferred over alternative strategies;
  • evidence supporting off-label prescribing;
  • informed consent discussions;
  • endocrine and metabolic assessment;
  • monitoring plans;
  • review arrangements;
  • contingency planning should adverse effects emerge.

Documentation should reflect a process of clinical reasoning rather than simply recording a prescribing decision.

Conclusion

Adjunctive aripiprazole remains a legitimate therapeutic option for selected patients with antipsychotic-induced hyperprolactinaemia. However, legitimacy does not eliminate professional responsibility.

Current GMC guidance, NICE recommendations and Royal College of Psychiatrists policy all point towards careful assessment, shared decision-making, systematic physical health monitoring and multidisciplinary management.

The legal authorities of Bolam, Bolitho and Montgomery reinforce these professional duties by requiring that prescribing decisions are supported by logical clinical reasoning, informed by responsible practice, and accompanied by meaningful patient involvement.

Where a patient receiving depot antipsychotic treatment develops persistent hyperprolactinaemia alongside diabetes mellitus or other endocrine abnormalities, the question should not simply be how to suppress prolactin. The more important question is whether the patient requires comprehensive endocrine investigation before additional psychotropic medication is introduced.

In many such cases, early referral to a consultant endocrinologist, combined with a multidisciplinary review of the antipsychotic regimen, is likely to represent the most clinically robust and the most legally defensible course of action.

This is why a precision based approach to psychiatry is necessary and not the antiquated and discredited system known as psychogenics, which far more resemble a belief system than any modern scientific evidence based medicine system. 

The psychogenic ‘symptom’ based approach to diagnosis is more a relic of the early 20th century than an evidence based medicine model and in the main health trusts still relying on this are likely lazy and dogmatic and have failed to keep up with neurological research and appropriate training of staff.  Apart from the obvious distress this causes to patients and their loved ones it represents a retrograde attitude to advancing psychiatric and neurological models.  Patents often spend years misdiagnosed and consequently incorrectly treated and more often than not detained in the forensic legal system that also sustains this intellectual bankruptcy in the medical professions. 

The underlying motivation of psychogenic psychiatry is isolation, deprivation of liberty and containment of what is often seem as more of a legal problem than one involving innocent victims of a medical pathology. 

There are several plausible and increasingly studied links between polyendocrine disorders and dysfunctional signaling in the mesolimbic system, particularly involving dopamine, stress hormones, immune signaling, and metabolic hormones. But the relationship is complex and usually indirect rather than a single unified disease mechanism.

The mesolimbic system (especially the VTA → nucleus accumbens dopamine pathway) regulates motivation, reward salience, reinforcement learning, mood, and aspects of energy regulation. Dysregulation in this circuit is implicated in depression, addiction, anhedonia, compulsive behaviours, schizophrenia-spectrum symptoms, and altered motivational states. 

Several endocrine systems feed directly into this circuitry:

1.     Cortisol / HPA axis

2.     Thyroid hormones

3.     Insulin and leptin

4.     Sex steroids

5.     Inflammatory cytokines

6.     Orexin and ghrelin signaling

7.     Prolactin-dopamine feedback loops

So when multiple endocrine systems become dysregulated simultaneously, as in polyendocrine syndromes mesolimbic signaling can adversely be affected.

A few examples of Autoimmune polyendocrine syndromes includes conditions like autoimmune polyendocrine syndrome (APS) often involve chronic inflammation, adrenal dysfunction, thyroid disease, diabetes, or gonadal hormone abnormalities. Cytokines and glucocorticoid instability can alter dopamine neuron firing and reward processing. Chronic inflammatory states are increasingly associated with reduced dopaminergic motivation signaling and anhedonia. 

Thyroid dysfunction.  Hypothyroidism can blunt dopaminergic tone and produce apathy, reduced motivation, depression and cognitive slowing

Hyperthyroidism can produce anxiety, agitation, reward/salience dysregulation and sometimes psychosis-like symptoms

These effects likely involve mesocorticolimbic dopamine modulation. The mesolimbic pathway is highly sensitive to glucocorticoids. Chronic excess cortisol can alter reward salience and stress responsivity, while adrenal insufficiency can impair motivation and emotional regulation. Stress-hormone modulation of VTA dopamine neurons is well established. 

Diabetes and insulin resistance influences. Insulin receptors are expressed in mesolimbic dopamine regions. Impaired insulin signaling can alter reward valuation, food motivation, impulsivity, and dopaminergic transmission. This is one reason metabolic disease and compulsive eating/addiction phenotypes overlap neurobiologically. 

Prolactin and dopamine.  There is a direct endocrine-dopamine loop. Dopamine inhibits prolactin release through D2 receptor signaling. Disorders involving prolactin, pituitary dysfunction, or dopamine blockade can therefore affect motivation, libido, affect, and reward processing. 

There is also an emerging idea that some syndromes that appear “psychiatric,” “metabolic,” and “endocrine” at the same time may involve shared network dysfunction between hypothalamic regulation, immune signaling, salience/reward circuitry and autonomic regulation

That overlap is especially discussed in chronic stress disorders, obesity/metabolic syndrome, inflammatory illnesses, chronic pain syndromes and some neuroimmune conditions


A mesolimbic abnormality would not usually be considered the primary cause of a polyendocrine disorder in mainstream medicine.  More commonly endocrine dysfunction alters mesolimbic signaling, or both are affected by a third process (autoimmune, inflammatory, genetic, developmental, or stress-related).

So the association is biologically credible and supported by growing evidence, but it is not yet a fully unified or clinically standardized framework.

For all parents and carers affected by barring/heavy ongoing restrictions, this blog is for you. It is regarded as totally unacceptable by the Care Minister (Stephen Kinnock however this is the reality for many in the UK. The ITN programme explored effects on some vulnerable person, parents and carers affected but the sad reality is that this situation is widespread, nationwide with many affected – thousands of vulnerable people are currently incarcerated on MH units for many years, not being properly assessed for physical health/neurological conditions such as FND, epilepsy, denied pathophysiological referrals/tests under neurology, endocrinology and immunology. Others in the community are likewise affected. Following a seizure for instance referral should be made according to Nice Guidelines NG217 within two weeks to see a specialist and there are specific guidelines for delirium. There are families whose vulnerable relative has been sent a long distance away, making visits difficult. It is wrong parents and carers are treated in such a dismissive manner, excluded from care meetings and any involvement by the NHS and certain care homes backed by Local Authorities. For those who complain the ultimate bullying is to deny contact or restrict contact without proper review, often for years on end. This has a widespread, devastating effect on families. On Mother’s Day my thoughts went out to all mothers who have no contact. It is a violation of human rights under Article 8 HRA to the vulnerable person and their families. I hope that something is done about this situation by the Government, especially with regard to neglect towards physical health and denial of pathophysiological tests to that person.

[Mother/Father’s Name]
[Address]
[Postcode]
[Email / Telephone]
[Date]

Clinical Management Team
[Hospital / Trust Name]
[Ward / Unit Name]
[Hospital Address]

Formal Request for Review of 2:1 Supervision and Written Reasons

Dear Clinical Management Team,

Re: 2:1 Supervision During Visits With My Relative (Son/Daughter)

I am writing as the mother of [Patient’s Name] regarding the requirement that two members of staff supervise my visits with my daughter.

While I understand that hospitals must manage risk appropriately, I am concerned that the requirement for two-to-one (2:1) supervision during my visits appears to have been imposed for some time without any clear explanation being provided to me, and without any indication that the restriction has been regularly reviewed.

As you will be aware, decisions affecting detained patients must comply with the Mental Health Act 1983and the guiding principles contained within the Mental Health Act Code of Practice.

The Code of Practice provides that:

·       Paragraphs 1.2 and 1.8 require that patients should only be subject to restrictions that are necessary and proportionate, and that the least restrictive option must be considered.

·       Paragraph 1.5 requires that any restrictive intervention must have a clear purpose and must not be imposed simply as a matter of routine.

·       Paragraph 1.7 emphasises the importance of respect, dignity and maintaining relationships with family members.

In addition, the continued imposition of 2:1 supervision during family visits interferes with the patient’s right to family life under Article 8 of the European Convention on Human Rights, which forms part of UK law through the Human Rights Act 1998. Any such interference must therefore be necessary, proportionate and capable of clear justification.

The presence of two staff members during visits makes it extremely difficult for my son/daughter and I to have normal private conversations and significantly affects our ability to maintain a meaningful family relationship.

If this restriction has not been regularly reviewed against current risk, it raises a concern that the requirement may be operating as a routine or blanket restriction, rather than a proportionate response to an identified risk.

Accordingly, I would be grateful if you could please provide the following information:

1.     The clinical rationale for imposing 2:1 supervision specifically during my visits.

2.     The dates and outcomes of all reviews of this restriction since it was first introduced.

3.     The risk assessment(s) currently relied upon to justify maintaining this level of supervision.

4.     Whether less restrictive arrangements for family visits have been considered.

5.     The date when this restriction will next be formally reviewed.

If this requirement has not been subject to regular and documented review, I am concerned that the continued imposition of 2:1 supervision during my visits may be disproportionate and therefore potentially unlawful.

For the avoidance of doubt, this letter should be treated as a formal request for written reasons for the restriction currently being imposed, and I would be grateful for a written response within 14 days.

If it would assist, I would also be happy to discuss the matter with the clinical team so that an arrangement can be agreed which appropriately balances safety with my son/daughter’s right to maintain a normal family relationship.

Yours sincerely,

[Mother’s Name]

HERE ARE THE GUIDELINES AND THOSE REGARDING SEIZURES AND DELIRIUM FOR ANYONE AFFECTED

NICE Guideline NG10 – Violence and Aggression: Short-Term Management in Mental Health Settings, and NHS Trust Enhanced Observation Policies.

Risk assessments must be regularly reviewed

The guideline requires continuous review of risk management plans:

Risk assessments and risk management plans should be regularly reviewed, and care plans must be based on accurate and thorough risk assessments.

This principle directly affects enhanced observation levels such as:

· 1:1 observation

· 2:1 observation

· constant observation

If the observation level is not being reviewed regularly, it may breach national clinical guidance.

How NG10 Connects to 2:1 Supervision

Although NG10 does not specify the exact term “2:1 supervision”, it governs the restrictive interventions and observation frameworks that hospitals rely on when implementing such measures.

Typical NHS observation levels include:

Observation level Description

General

observation periodic checks

Intermittent

observation checks at set intervals

Within eyesight continuous observation

Within arm’s

length very high-risk monitoring

2:1 observation two staff members observing the patient

Under NICE and NHS policy:

· the clinical justification must be documented

· the observation must be reviewed frequently

· it must remain proportionate and justified by evidence

PRE-ACTION PROTOCOL LETTER TO FOLLOW UP IF NO RESPONSE

[Your Name] [Your Address] [Postcode] [Email / Telephone]

Date: [Insert Date]

BY EMAIL AND RECORDED DELIVERY

The Responsible Clinician The Ward Manager The Mental Health Act Office [Name of NHS Trust] [Hospital Address]

LETTER BEFORE ACTION – INTENDED COURT OF PROTECTION PROCEEDINGS

Re: [Patient’s Full Name / DOB] – Unlawful Contact Restrictions and 2:1 Supervision

Dear Sir/Madam,

I write formally concerning the ongoing restrictions placed upon my contact with [Patient’s Name], who is currently receiving care at [Ward/Hospital] under the responsibility of [NHS Trust].

This letter constitutes a formal Letter Before Action and should be treated as notice that, unless the matters set out below are addressed urgently, I intend to issue proceedings in the Court of Protection without further notice.

Unlawful Interference With Family Life

The Trust is currently restricting or controlling my contact with [Patient’s Name], apparently on the basis of the patient’s 2:1 supervision / enhanced observation level.

These restrictions amount to a serious interference with family life, protected under the Human Rights Act 1998 – Article 8 (Right to respect for family life)

Any interference with Article 8 rights must be lawful, necessary, proportionate and supported by evidence of risk

At present, the Trust has failed to demonstrate that these requirements are satisfied.

Statutory Duties Under the Mental Capacity Act

If the patient lacks capacity to determine contact arrangements, the Trust is under a statutory duty to act in accordance with the Mental Capacity Act 2005.

In particular:

· Section 4 requires all decisions to be taken in the person’s best interests, including proper consideration of family relationships.

· Sections 15 and 16 confer jurisdiction on the Court of Protection to determine issues relating to welfare, contact, and care arrangements.

Where contact between a patient and family member is restricted without lawful justification, the Court may make binding welfare orders regulating contact and directing the NHS Trust to amend its care arrangements.

Observation Policies and 2:1 Supervision

The Trust appears to be relying on the patient’s 2:1 supervision level as justification for the present restrictions.

Enhanced observation measures of this type are governed by NICE Guideline NG10 – Violence and Aggression: Short-Term Management in Mental Health Settings, and NHS Trust Enhanced Observation Policies.

These policies require that:

· Enhanced observations must be risk-based and individually justified

· Observation levels must be subject to regular clinical review

· The least restrictive principle must be applied

· Restrictions on family contact must be supported by a specific risk assessment relating to that contact

Enhanced observation does not provide lawful authority for blanket restrictions on family contact.

Serious Procedural Concerns

Despite repeated requests, the Trust has failed to provide:

· the risk assessment said to justify restricting family contact

· the care plan provisions governing such restrictions

· observation review records relating to the patient’s 2:1 supervision

· any evidence demonstrating that less restrictive alternatives have been considered

If these documents do not exist, the current restrictions may be unlawful and incompatible with both the Mental Capacity Act and Article 8 rights.

Required Disclosure

In order to avoid litigation, the Trust is requested to provide the following within 14 days:

1. The patient’s current care plan.

2. All risk assessments relating to family contact.

3. All observation level review records relating to the patient’s 2:1 supervision.

4. The policy or clinical basis relied upon to restrict family contact.

5. Confirmation of the schedule and procedure for reviewing observation levels and associated restrictions.

Intended Court of Protection Application

If the above information is not provided, or if the current restrictions remain in place without lawful justification, I will issue proceedings in the Court of Protection seeking:

· A declaration regarding the patient’s capacity to decide contact

· A declaration that the current restrictions are unlawful and disproportionate

· A welfare order regulating contact between the patient and family members

· Directions requiring the Trust to amend the care plan and observation arrangements

· Any further relief the Court considers appropriate

The Court of Protection has the power to make binding orders requiring NHS Trusts to alter care arrangements where they unlawfully interfere with family life.

Opportunity to Resolve Without Litigation

Litigation can still be avoided if the Trust:

· reviews the current restrictions urgently,

· provides the documentation requested above, and

· confirms that the patient’s contact with family will be managed in accordance with statutory duties and the least restrictive principle.

If no satisfactory response is received within 14 days, proceedings will be commenced without further notice.

Yours faithfully,

[Your Name]

NICE NG217 Guideline on Seizures

1. Urgent referral after first seizure or recurrence

NG217 1.1.1 – First suspected seizure

“Refer children, young people and adults urgently (for an appointment within 2 weeks) for an assessment after a first suspected seizure”
— NICE NG217¹, Recommendation 1.1.1. 

This uses urgent referral, defined by NICE as an appointment within 2 weeks, for anyone after a suspected seizure.

NG217 1.1.2 – Seizure recurrence

“Refer children, young people and adults urgently (for an appointment within 2 weeks) for an assessment if they have a seizure recurrence after a period of remission.”
— NICE NG217¹, Recommendation 1.1.2. 

A recurrence after remission is repeated and unexplained, and under NICE this is explicitly urgent — same timeframe as first seizure.

2. Implication for repeated unexplained seizures

Even though NG217 does not use those exact words (“repeated unexplained seizures”) in a standalone recommendation, the guidance is clear from these linked recommendations:

  • Any recurrence (repeated seizure) after a seizure-free period triggers the same urgent referral timing as a first seizure.
    → This means 2 weeks maximum to specialist assessment. 
  • The guideline does not recommend routine or non-urgent pathways for recurrent or potentially multiple unexplained seizures in adults or children. 

3. Investigations are recommended promptly too

While NG217 separates referral timing (urgent within 2 weeks) from investigations, it also states:

EEG timing

“…if an EEG is requested after a first seizure, perform it as soon as possible (ideally within 72 hours after the seizure).”
— NICE NG217, EEG section. 

This supports early investigation following urgent specialist review.

Neuroimaging

“Offer brain neuroimaging tests if an underlying structural cause is suspected…”
— NICE NG217. 

This reinforces that after urgent specialist assessment, relevant investigations should not be unreasonably delayed when clinically indicated.

SituationNICE RecommendationTimeframe
First suspected seizureUrgent specialist referral (1.1.1)Within 2 weeks
Repeat seizure after remission (i.e., repeated unexplained)Urgent specialist referral (1.1.2)Within 2 weeks
EEG after suspected seizureEarly investigationIdeally within 72 hrs
Neuroimaging if neededPrompt test as indicatedNo specified fixed max—but not deferred

Key takeaway from NICE wording

NICE NG217 does not permit prolonged routine delays for repeated unexplained seizures. According to its urgent referral recommendations (1.1.1 & 1.1.2):

A recurrence or repeated unexplained seizure merits the same urgent (2-week) referral as a first seizure. 

Follow-up investigations (EEG, imaging) should then be arranged as soon as clinically appropriate, not deferred indefinitely. 

NICE GUIDELINES  CG103  DELIRIUM

Before the referral meeting and most certainly before the scan a patient needs to be properly rested to avoid physiological confounders.  

Good clinical practice in cognitive and neurological assessment requires that potentially reversible causes of impaired cognition are identified and corrected before diagnostic conclusions are drawn.

Under NICE guideline CG103 (Delirium: prevention, diagnosis and management), clinicians must assess for acute physiological contributors to confusion, including dehydration, infection, hypoxia, hypoglycaemia, metabolic disturbance, and medication effects. The guideline emphasises that delirium is common, serious, and frequently reversible, and that failure to detect underlying medical causes risks misdiagnosis.

Accordingly, cognitive assessment should occur only when the patient is medically stable. Good practice therefore includes:

  • Excluding delirium and acute illness
  • Correcting dehydration and metabolic abnormalities. (nourishment, breakfast to avoid hypoglycaemia)
  • Reviewing medications and substances
  • Managing pain and sleep disturbance (a proper nights sleep before to avoid confusion due to tiredness) 
  • Ensuring appropriate sensory aids and a suitable testing environment

While CG103 does not explicitly state that a patient must be “relaxed and properly nourished,” its requirements to identify and treat reversible contributors to confusion implicitly support optimisation of physiological and environmental conditions prior to assessment.

In summary, consistent with CG103, cognitive evaluation should be undertaken under conditions that minimise reversible confounders to ensure diagnostic validity and patient safety.

Evidence of New / Escalating Criticism of Lincolnshire Adult Social Care

Ombudsman / Care Act Failures

A recent (April 2025) LGO decision (ref 24-003-962) found fault in how LCC (via Lincolnshire Partnership NHS Trust, acting for LCC) handled a Care Act assessment and care plan for a person with mental and physical health needs. Specifically: no advocate was involved despite communication difficulties, care was inconsistent, and there was poor communication / information-sharing — this caused distress. Local Government Ombudsman

Another case (Centre for Adults’ Social Care report, June 2025) describes a woman with complex mental health needs whose move into the county triggered fragmented / inadequate support. LCC (via its partner trust) failed to provide consistent care, arranging too few hours vs her assessed need, and she suffered distress, hospital admissions, and isolation. cascaidr.org.uk

A separate Ombudsman ruling (July 2025) relates to transition from children’s to adult services. LCC made “errors in care package decisions and communications” for a young adult with disabilities (including transport for day-centre attendance), causing her to miss care. cascaidr.org.uk+1

Healthwatch Lincolnshire Feedback

The Healthwatch Lincolnshire report (2025) includes a case (Feb 2025) of an adult social care user whose health needs were compromised because of lack of proper care provision. According to the report, the person is a wheelchair user and needs increased care post-operation, but LCC could not guarantee provision for that increased care, leading to the cancellation of a surgery. Healthwatch Data

While this is not explicitly “mental health care,” it shows stress / risk in how adult social care assesses and responds to changing care-need demands — including when health interventions (surgery) would make care needs temporarily more intense.

Local Media / Policy

Lincolnshire World reported very recently (Oct 2025) that LCC officials are considering reducing the number of “active recovery beds” (mental-health-related step-down beds) from 29 to 24. That’s a significant signal: reducing capacity in part of the mental health recovery system could be seen as cutting back or deprioritising mental health care for adults. LincolnshireWorld

Complaint Statistics

In its 2024–2025 complaints report, LCC notes that 23 complaints from that year were escalated to the LGSCO about adult care. Lincolnshire County Council

While not all these will be about mental health, it suggests a non-trivial volume of serious complaints in the adult care sphere.

Interpretation & Assessment

The Ombudsman findings are the strongest concrete evidence: there are real cases where LCC has failed to provide or plan care properly for people with mental health or complex needs. These are not isolated paperwork mistakes, they have caused distress and had a material negative impact.

The Healthwatch case indicates that some people struggle to get social care to respond when their health needs (which may interact with mental health) change. That could suggest capacity / resource problems in LCC’s adult social care provision.

The proposal to reduce active recovery beds is worrying: if implemented, it could worsen recovery pathways for people needing step-down mental health care. That could be a policy direction that reduces service rather than expands it.

However, the CQC’s most recent (pilot) assessment of LCC adult social care is still “Good”, which means from a regulator’s perspective, the overall adult social care system is functioning reasonably well (though not without room for improvement, especially in certain pathways). Lincolnshire County Council+2Care Quality Commission+2

There is new and escalating criticism of LCC’s mental-health-related adult care: through Ombudsman decisions, Healthwatch reports, and potentially in policy (bed reductions).

The criticisms are not wholesale systemic collapse, but they do raise serious concerns about how well LCC is meeting the needs of vulnerable adults — particularly those with complex mental health or changing care needs.

Some of the key pressure points: assessment and care planning, continuity / consistency of care, capacity in recovery services, and responsiveness to changing needs.

Briefing Summary: Criticisms of LCC Adult Mental Health Care (2023–2025)

1. Financial & Demand Pressures

LCC’s 2024/25 financial performance review reports a significant overspend in mental health adult care:

Community supported living (for working-age / mental health clients) overspent by £3.2 million, of which £1,060,000 relates to “Growth in demand for DoLS / LPS” (Liberty Protection Safeguards) due to a much higher-than-expected increase in client numbers (94 new clients vs 25) planned). lincolnshire.moderngov.co.uk+2lincolnshire.moderngov.co.uk+2

Long-term residential mental health care also saw growth: 27 new clients, resulting in a £0.408 million overspend. lincolnshire.moderngov.co.uk+1

Short-term care (mental health) clients exceeded budgeted numbers, adding further financial pressure. lincolnshire.moderngov.co.uk+1

The budget for 2025/26 continues to forecast rising demand in mental health: LCC recognizes a 3–6% annual growth in working-age / mental health service demand. lincolnshire.moderngov.co.uk

In its executive meeting (Aug 2025), the Overview & Scrutiny Management Board flagged this as a “volatile and risk-based” budget area, with ongoing close monitoring. lincolnshire.moderngov.co.uk

Implication: LCC may be under-estimating both the scale and pace of demand growth for mental health care, risking repeated overspends and service strain.

2. Service Reduction Controversies – Active Recovery Beds

Local media (LincolnshireWorld) report that LCC is proposing to reduce the number of Active Recovery Beds (ARBs) from 29 to 24. LincolnshireWorld

These beds are used for people stepping down from hospital but not yet ready to return home, reducing them could limit “step-down” capacity. LincsOnline+1

The Council argues the reduction aligns with “presenting demand” and will improve occupancy (from ~70% to ~90%). LincolnshireWorld

However, some councillors have expressed concern: e.g., whether this reduction under-provides in the face of broader NHS / social care pressures. LincolnshireWorld+1

Implication: The proposed cut could undermine recovery capacity; critics worry demand may outstrip reduced supply, especially as patients leave hospital.

Ombudsman Findings – Assessment & Care Planning Failures

In LGO decision 24-003-962 (April 2025), the Ombudsman upheld a complaint against LCC:

LCC (via its partner, Lincolnshire Partnership NHS Trust) failed to provide reasonable adjustments in a Care Act assessment despite the complainant’s mental and physical health issues. Local Government Ombudsman

The decision-making was inconsistent: carers were not familiar with her, there was inadequate handover, and no advocate was involved even when needed. Local Government Ombudsman

The Council also made housing decisions (moving the person) that the Ombudsman found unsuitable. Local Government Ombudsman As a remedy: LCC must apologise and pay a sum to acknowledge the injustice caused. Local Government Ombudsman

A separate Cascaidr analysis (July 2025) highlights another case: LCC failed to properly manage a care package for a person with mental health and possibly autistic traits. Adult Social Care Centre

The complaint noted that LCC did not properly assess the person’s capacity or share information with providers, leaving her without adequate support. Adult Social Care Centre

The analysis argues that LCC’s assessment systems / legal understanding may be weak in dealing with complex, capacity-fluctuating mental health cases. Adult Social Care Centre

Another Cascaidr / Ombudsman case (Sept 2025): poor management of transition from children’s to adult services for a young woman with disabilities (including mental health / supportive needs). Adult Social Care Centre

The Council initially promised transport + day-centre attendance but later withdrew transport without confirming that a closer centre could meet her needs, resulting in missed care. Adult Social Care Centre

The Ombudsman found LCC at fault: decisions were made without fully checking alternatives; communication was confusing; and there was procedural failure in its authorisation processes. Adult Social Care Centre

The Council was required to apologise and pay a symbolic amount, and to remind staff about proper internal authorisation procedures. Adult Social Care Centre

Implication: There appear to be systemic weaknesses in LCC’s assessment, planning, and communication processes especially for people with complex mental health needs or transitioning from children’s services. This raises risk of unmet need, distress, and legal non-compliance.

Local Advocacy / Healthwatch Voice

Healthwatch Lincolnshire’s 2024/25 Annual Report shows increasing engagement, but also highlights challenges: while not all issues are mental health–specific, many concern social care access, capacity, and unmet needs. healthwatchlincolnshire.co.uk

In the 2024–25 interim work plan, Healthwatch identified “influencing decision-makers” and “addressing underrepresented groups” as key priorities, suggesting they are pushing for more responsive, inclusive care provision. healthwatchlincolnshire.co.uk

Local media commentary (LincolnshireWorld) also notes LCC acknowledging rising complexity in mental health care packages and growing costs:

“a major contributor to cost pressures … an increase in demand and complexity of mental health services.” LincolnshireWorld

Implication: Local citizen-led organisations are raising the alarm about escalating demand, growing complexity, and pressures on mental health adult care — suggesting these are not just financial issues but affect quality and accessibility.

Strategic & Systemic Risks

During a Council Executive meeting (July 2025), a councillor (Steve Clegg) explicitly questioned LCC’s mental health community support overspend. The Executive Director (Adult Care) acknowledged demand is rising “faster than elsewhere” and hinted at concerns over the quality of existing service delivery. Open Council Network

LCC’s written evidence to Parliament (recent submission) also warns that demand for adult mental health care is exceeding previous forecasts, putting “increasingly strained” pressure on the system. UK Parliament Committees

Implication: The financial and service pressures are not short-term or one-off: there’s a real risk that demand continues to outpace LCC’s capacity, potentially degrading care quality or forcing tough decisions (like bed cuts).

Overall Summary

Demand is rising fast: LCC is seeing more working-age / mental health adult clients than budgeted for, driving large cost overruns.

Service capacity is under threat: Proposed reductions in Active Recovery Beds raise concerns about recovery pathways.

Professional standards are being questioned: Ombudsman decisions show LCC sometimes fails in assessments, support planning, and legal duties, especially for those with complex, fluctuating mental health needs.

Local voices (Healthwatch, Councillors) are pushing back: There is growing unease about how LCC is managing this demand, both financially and in terms of service delivery.

Strategic risk is real: Unless LCC adapts, by increasing capacity, improving assessment processes, and planning strategically — there is a danger that its mental health adult care provision will become unsustainable.

A separate Cascaidr analysis (July 2025) highlights another case: LCC failed to properly manage a care package for a person with mental health and possibly autistic traits. Adult Social Care Centre

The complaint noted that LCC did not properly assess the person’s capacity or share information with providers, leaving her without adequate support. Adult Social Care Centre

The analysis argues that LCC’s assessment systems / legal understanding may be weak in dealing with complex, capacity‑fluctuating mental health cases. Adult Social Care Centre

The Care Act 2014 requires councils to assess any adult who appears to need care and support, regardless of financial circumstances, and to involve the individual and any carer or anyone else they wish to be involved. Assessments must be timely, involve the person, and consider their wellbeing and desired outcomes. Care and support plans must be co-produced, include a personal budget, and be responsive to changing needs. 

When a person moves between council areas, there are statutory duties to ensure continuity of care (section 37), but they do depend on the destination council knowing that the person is on their way. 

Councils must also consider reasonable adjustments for communication and mental health needs, and ensure advocacy is provided where it is triggered by the concept of the person’s substantial difficulty engaging in the Care Act processes of assessment, care planning or revision (regardless of having a willing relative) without one being appointed. 

The failure to provide adequate care and support, or to arrange advocacy, is a breach of statutory duty.  It renders the assessment invalid, in community care and public law and that has been the case since the Haringey judgment in 2015.

Every year, tens of thousands of vulnerable adults, elderly people with dementia, individuals with learning disabilities, psychiatric patients are subject to care decisions under the UK’s Mental Capacity Act 2005 (MCA). The Act was designed as a safeguard: to ensure their rights, to assess whether they can make decisions, and to limit the use of coercion. But a growing body of evidence suggests that many Local Authorities and NHS trusts are failing at that mission. Rather than protecting autonomy, systems designed to shield people from abuse may be enabling institutional convenience.

A System Under Pressure

According to the Care Quality Commission (CQC), the system overseeing deprivation of liberty is creaking. Their 2023–24 report on DoLS (Deprivation of Liberty Safeguards) found that many supervisory bodies are “significantly under-resourced.” Some local authorities told CQC they lack enough assessors and cannot keep pace with soaring demand. Care Quality Commission

One local authority said they would “be doing this for around 18 months just to clear” their backlog if no new applications came in. Care Quality Commission

The problem: only 19 % of DoLS applications are completed within the legal limit of 21 days; many people wait between 12–18 months. Local Government Lawyer+2Care Quality Commission+2

Resource-constrained councils cite staffing shortages and rising caseloads as the key drivers. Local Government Lawyer

This is not a quirk – it’s systemic. SCIE (the Social Care Institute for Excellence) analysis shows 67% of local authorities assessed by the CQC still “require improvement” in their DoLS arrangements. Local Government Lawyer

When Safeguards Are Delayed, Rights Are Denied

The delays are not harmless. In some cases, people who should have formal protections under the MCA are left in legal limbo. The Local Government & Social Care Ombudsman (LGSCO) has repeatedly raised red flags:

In a high-profile case, Surrey County Council had 5,700 outstanding DoLS requests as of 31 March 2022. Bond Solon

The average time to complete an assessment in that area was 345 days, more than double the national average of 154 days. Bond Solon

The Ombudsman found that Surrey appeared to rely on an “ADASS screening tool” to prioritise, but in so doing, “were not following the legal criteria contained in the Mental Capacity Act … around time frames.” Bond Solon

In another case, Southampton City Council was criticized for its high numbers of outstanding MCA assessments and DoLS applications (382 and 404 respectively), and for delaying assessments so long that people were restricted without the legal protections they ought to have. Local Government Lawyer

Misunderstanding, Misapplication, and Mis-training

Many of the problems stem not only from resource scarcity, but from widespread misunderstanding of the MCA among professionals:

Poor Understanding by Providers

In its 2022–23 monitoring report, CQC found that some providers did not properly implement the conditions of DoLS authorisations (e.g., access to places of worship or visits), meaning the restrictions imposed might not actually reflect the person’s best interests. Care Quality Commission There was also “poor recording of mental capacity assessments.” Care Quality Commission

In some mental health settings, CQC observed that staff did not clearly understand the interface between the MCA and the Mental Health Act, leading to poor decisions about which framework to use. Care Quality Commission

Lack of Training & Governance

According to a CQC report from 2013, care staff often misunderstood even the basics of the MCA, restraint was not always recorded or considered properly, and “best interests” decisions were sometimes poorly documented. Care Quality Commission

The same report noted that, in some services, there was little attempt to maximise a person’s capacity before resorting to restrictions. Care Quality Commission

Mental Capacity Law and Policy (a specialist commentary) analysed 139 “Notices of Proposal” from 2023–24 (when new providers were registering) and found that 66 related explicitly to noncompliance with the MCA. Mental Capacity Law and Policy

Institutional Incentives Over Individuals’ Best Interests

Beyond lack of training, some systemic incentives risk tilting decisions in favour of institutions rather than individuals:

The Social Care Institute for Excellence (SCIE) argues that resource pressures are pushing councils toward “triage approaches”: using screening tools to prioritise some cases, leaving others in backlog indefinitely. Local Government Lawyer

CQC’s State of Care report observed a “wide variation” in how different local authorities manage applications, with some applying blanket restrictions to all residents, even when less restrictive options might suffice—raising the question of whether these measures are more about institutional convenience than individual rights. Community Care

In its analysis, CQC also noted a “misconception among some providers that a DoLS application equated to an authorisation being in place.” In other words, some staff may believe applying for DoLS is enough, without fully thinking through what restraints should or should not be authorised. Community Care

Consequences for People

The human cost is considerable. The Health & Care Professionals Alliance (HCPA) published a report, The Right to Decide, collating investigations by the Ombudsman:

One person was removed from their family home in the dead of night without prior notice, without formal capacity assessments. HCPA

Another was moved 15 miles away to a care home, but no adequate best-interests process had been documented; friends and family felt cut out of decision-making. HCPA

In a third case, the complaint upheld by the Ombudsman noted that organizations had failed to collaborate and ensure the person received the care they actually needed, rather than what was convenient. HCPA

Over one year (2016–17), the Ombudsman estimated that up to 20% of adult social care complaints they investigated concerned capacity or DoLS; 69% of those cases were upheld, indicating systemic failure. HCPA

Judicial and Legal Alarm Bells

Legal scrutiny has also exposed deeper problems in how capacity assessments are carried out:

A recent Mental Capacity Report (March 2025) highlighted how local authority assessments sometimes rely on “unstructured” or flawed capacity-assessment forms that fail to align with the statutory framework of the MCA. Judges have pointed out the need for assessments to be “evidence-based, person-centred … not made to depend … upon the identification of a so-called unwise outcome.” Mental Capacity Law and Policy

The report also emphasizes the mental/clinical versus legal distinction: “insight is a clinical concept, whereas decision-making capacity is a legal concept.” When that line is blurred, local authorities risk wrongly judging people to lack capacity. Mental Capacity Law and Policy

Reform on the Horizon – But Progress Is Slow

The system’s flaws are well known, and reform has been promised for years. The Law Commission criticized the existing DoLS framework as a “bureaucratic nightmare” back in 2017, estimating that thousands were being held without proper authorisation. The Guardian Reform is due via the Liberty Protection Safeguards (LPS), but even the transition has collided with delays, confusion, resource constraints, and lack of clarity among commissioning bodies. Care Quality Commission+1

Why This Looks Like “Misuse”

All this is not necessarily sinister. It may not always be malicious. But the patterns suggest that institutional pressure (caseload, funding) is influencing how the MCA is applied.

“Backlogs” are used to justify delayed or reduced protections, potentially depriving people of their legal rights.

Poor understanding of the law among providers and assessors means that deprivation of liberty sometimes happens without rigorous, lawful assessment.

Some providers treat DoLS applications as a “box tick” rather than a serious, rights-based safeguard.

There is little consistency in how authorities prioritise or justify cases, raising questions about equity and accountability.

In short: the system designed to protect autonomy may be bending to convenience.

Voices of Concern

Advocacy groups and legal commentators argue that the very architecture of DoLS makes it vulnerable to misuse.

Families bereft of influence after capacity decisions feel marginalised.

The CQC has repeatedly warned of human rights risks, urging “urgent reform” to ensure people do not remain indefinitely in restrictive settings without proper legal safeguards. Community Care

What Needs to Change

From the evidence, three priorities emerge:

Local authorities desperately need more staff trained in MCA assessments, best-interests decision-making, and authorising deprivations of liberty.

Providers must deepen their understanding of not just how to assess capacity, but why; training must embed respect for autonomy, not just risk management.

There should be clearer mechanisms to hold councils and trusts accountable when they fail or delay assessments, including robust advocacy for individuals and families, and accessible appeals.

The Mental Capacity Act 2005 was meant to be a guardian of dignity, choice and protection. But in too many cases, it is being stretched—by overwork, underfunding, misunderstanding, and institutional inertia—into something else: a tool that limits liberty under the guise of safeguarding. The neglect may not always be malicious, but the effect is often the same: vulnerable people left waiting, unheard, and powerless.

Unless reform accelerates, the very safeguards meant to protect them may end up being the prison.

Locked In: How the Mental Capacity Act Is Being Bent

A 2023–25 Court of Protection Timeline

Since 2023, a steady stream of Court of Protection and family-court judgments, regulator reports and ombudsman decisions have drawn a picture of a system stretched to breaking. Chronic DoLS (Deprivation of Liberty Safeguards) backlogs, inconsistent legal reasoning about when someone is “deprived of liberty”, and repeated judicial reminders that local authorities and NHS bodies must follow the statutory safeguards.

The evidence does not usually show conspiratorial intent; it shows routine institutional pressure (backlogs, triage, lack of expertise) producing unlawful or inadequate use of the Mental Capacity Act 2005 (MCA). Below I trace the most important court decisions and official findings from 2023–2025 that illustrate how those failures translate into people losing rights and legal protections.

Quick summary of the headline evidence (short)

DoLS backlogs and missed statutory timeframes have been documented by the CQC and Ministry of Justice statistics, leaving many people without timely authorisations. Care Quality Commission+1

The Local Government & Social Care Ombudsman (LGSCO) has upheld complaints where councils failed to assess DoLS requests within legal timeframes, finding people “wrongfully deprived” or left restricted without proper authorisation. Local Government Lawyer+1

Court of Protection judgments in 2023–2025 illustrate recurrent themes: disputes about whether an intervention amounts to a deprivation of liberty, whether the Mental Health Act or MCA should apply, and whether authorisations or court orders were achieved lawfully and with proper best-interests reasoning. Mental Health Law Online+2Court of Protection Hub+2

Timeline: key court decisions, regulator findings and turning points (2023–2025)

2023 Rising Court workloads; judicial scrutiny of care plans

Jan–Jun 2023 Lancashire & South Cumbria NHS Foundation Trust v AH [2023] EWCOP 1

HHJ Burrows considered whether a proposed placement and care regime for AH involved a deprivation of liberty, and emphasised the need for careful, evidence-based assessment of whether restrictions go beyond what is necessary and lawful; the judgment shows how complex clinical/risk decisions become legal disputes requiring judicial oversight when the boundaries between care and confinement are blurred. Mental Health Law Online

May 2023, Manchester University Hospitals NHS Foundation Trust & JS [2023] EWCOP 12 A judgment explored the expiry of a Mental Health Act authority and the resulting question whether a person then lacked lawful authorisation and therefore was being deprived of liberty under the MCA. The case emphasises the fragile interface between the Mental Health Act and the MCA and how administrative lapses can convert clinical placements into unlawful deprivations. Court of Protection Hub

Mid-2023, Surge in Court of Protection workload and DoLS applications Commentators and the National Deprivation of Liberty Court reported rising numbers of applications — Courts were seeing more DoL applications and challenges, creating delay and pressure on judicial lists. These workload pressures mirror the operational backlogs being reported by authorities. Community Care+1

2024. Backlogs, legal uncertainty and children’s cases

Early–Mid 2024. Court decisions emphasise rigor of capacity reasoning Judges continued to insist capacity and best-interests assessments be person-centred and evidence-based; some hearings were listed (or refused on paper authorisation) because the court would not rubber-stamp restrictions in the absence of robust reasoning. The “failed to authorise on the papers” approach demonstrates judicial unwillingness to accept weak or incomplete local authority evidence. openjusticecourtofprotection.org

Mid–2024. Record Court activity and a spike in challenges. Ministry of Justice and reporting bodies recorded sharp rises in DoL/Court of Protection activity (for example, large increases in challenges and applications in early-2024), feeding a public debate that some deprivation orders are being used as a cheaper, quicker option than community care packages. Campaigners argued the rise signalled an institutional shift towards authorising restrictions rather than funding viable community alternatives. The Guardian+1

2024 Children’s deprivation-of-liberty jurisprudence. The family and High Court continued to revisit whether parental/local-authority consent can lawfully authorise confinement of children (cases flowing from Lincolnshire CC v TGA (2022) and related 2024 hearings). These decisions underscore how confusion about who can legally “consent” to restrictions risks inappropriate or unreviewed confinements for young people. (The Court of Appeal would then revisit these issues in 2025.) 39 Essex Chambers+1

2025 Consolidation, pushback and appellate refinement

Jan–Apr 2025. Continued judicial clarification (Re V (Profound Disabilities) and related High Court judgments)

High Court judgments in 2025 examined the fine line between care that meets profound needs and state action amounting to deprivation of liberty, finding in some instances that severe disability (and incapacity to leave) meant there was no Article 5 deprivation because the person could not, physically, assert liberty in the ordinary sense. These nuanced rulings highlight inconsistency in outcomes across jurisdictions and how factual differences produce different legal results, which in turn creates inconsistent practice by local authorities. Mental Health Law Online+1

2024–2025. Ongoing CQC warnings and statistical picture CQC’s State of Care reporting for 2023–24 documented that only 19% of standard DoLS applications were processed within the statutory 21-day window and that over 120,000 people were awaiting authorisation at March 2024, a scale of backlog that the regulator described as a human-rights risk. The chronic backlogs and the use of risk-based triage were repeatedly flagged as drivers of unlawful or delayed authorisations. Care Quality Commission+1

April 2025. Court of Appeal revisits limits on local authority consent for children (J v Bath & NE Somerset Council & Ors [2025] EWCA Civ 478). The Court of Appeal corrected earlier Family Division reasoning and clarified that local authorities cannot simply “consent” to confinement for children in their care in the same way parents can, a ruling that tightened a prior area of legal uncertainty and reduced scope for local authorities to rely on loose consent arguments. This is an example of appellate courts pushing back where local practice had expanded the boundaries of lawful restriction. Mental Capacity Law and Policy

Representative examples where court/regulator findings show misuse (or unlawful application) of the MCA

Administrative or procedural failures that created unlawful deprivations. The Manchester University Hospitals case shows how expiry of an appropriate authorising power can leave a person without lawful authorisation; judges have been alert to gaps where no lawful regime was in place but the person remained restricted. Court of Protection Hub

Prioritisation/triage and backlog decisions producing restrictive outcomes without timely authorisation. CQC statistics and Ombudsman decisions (e.g., Surrey County Council LGSCO findings) document councils using screening tools and prioritisation, resulting in very long waits for DoLS assessments and people effectively restricted without legal protections. Care Quality Commission+1

Confusion at the MHA–MCA interface and inappropriate use of one regime to avoid another. Judgments have repeatedly had to untangle whether the Mental Health Act or the MCA should apply; errors or delays in determining the correct legal framework have led to contested deprivations of liberty that end up in court. Court of Protection Hub+1

Use of the inherent jurisdiction/family court in place of clearer statutory routes. In children’s cases, family courts’ use of parental consent or inherent jurisdiction to authorise confinement has provoked appellate correction (2024–25) because the practice risked leaving children without the specific statutory safeguards intended by the DoLS/LPS frameworks. 39 Essex Chambers+1

What the cases show about why misuse (or inadequate use) happens

Pulling the cases and reports together shows repeated causal drivers:

Capacity and DoLS workloads are outpacing resources. Authorities adopt risk-based triage and screening tools (documented by CQC and LGSCO). Care Quality Commission+1

Knowledge gaps and weak record-keeping. Courts regularly call for evidence-based, person-centred capacity assessments and find records are often inadequate. Mental Capacity Law and Policy

Legal uncertainty (children, the MHA–MCA interface, what constitutes “state responsibility”) leads to inconsistent practice; judges correct the approach but only after rights have been restricted. 39 Essex Chambers+1

Case snapshots (short, cited extracts you can follow up)

Lancashire & South Cumbria NHS Foundation Trust & Lancashire CC & AH [2023] EWCOP 1. HHJ Burrows authorises measures but stresses careful scrutiny of deprivation questions. (See mentalhealthlaw and Court of Protection Hub summaries.) Mental Health Law Online+1

Manchester University Hospitals NHS Foundation Trust & JS [2023] EWCOP 12. Judge found that once the MH Act authority expired, the person’s continuing restrictions triggered deprivation-of-liberty questions under the MCA. (Lesson: administrative lapse -> legal problem.) Court of Protection Hub

Stockport MBC v KB [2023] EWCOP 58 (reported analysis). Judicial analysis of community DoL applications and the kinds of medical evidence required (illustrates the court responding to poor or inconsistent local authority practice). Local Government Lawyer

Series of family/care cases on children (2022–2025). Lincolnshire CC v TGA (2022) spawned follow-on litigation and appellate correction in 2025; the arc shows local authorities and courts grappling with who may lawfully authorise confinement of children in their care. 39 Essex Chambers+1

Regulatory & statistical evidence. CQC: chronic DoLS backlogs and only 19% applications met statutory timescales (2023–24). LGSCO: formal findings that councils’ delays led to unlawful restriction in named investigations (e.g., Surrey). Ministry of Justice / court statistics: rising DoL applications and court challenges in 2024. Care Quality Commission+2Local Government Ombudsman+2

What this means for people and families (real effects shown in cases)

People have been left restricted for months without a lawful authorisation; families have been excluded from decision-making or told the only option is placement. Ombudsman and court reports give concrete examples of people moved long distances or denied contact because an adequate best-interests process was not carried out. Local Government Ombudsman+1

Conclusion — legal fixes are occurring, but slowly

Between 2023 and 2025 the courts have repeatedly had to step in to correct, fine-tune and sometimes rebuke local practice. The evidence is consistent: misuse is often not a deliberate plot but the predictable consequence of under-resourcing, inadequate training, inconsistent legal reasoning and the temptation to use deprivation orders as administratively convenient substitutes for proper social care packages. Appellate authorities (and the CQC/LGSCO) have pushed back, but only partly: operational backlogs and resource constraints mean the same problems recur across jurisdictions.

Hidden in Plain Sight: The Secrecy and Power of the Office of the Public Guardian

The role of the Office of the Public Guardian (OPG) in England and Wales is, on paper, laudable. Tasked under the Mental Capacity Act 2005 with protecting some of society’s most vulnerable, the mentally incapacitated, those with severe illness or debilitation, its remit should command public trust. 

Yet for many families caught in its orbit, the reality has been something quite different: an opaque system, court-enforced gagging orders, accusations of wrongdoing levelled at innocent relatives, and little meaningful public scrutiny.

Secrecy by Default

The Court of Protection (CoP), which often works in tandem with the OPG when deputies are appointed or decisions made about capacity, remains shrouded in confidentiality. The legal framework makes it a contempt of court to publish a judgment unless the judge gives permission. As one commentary observed:

“We are finding that a significant minority of Transparency Orders prohibit identification of public bodies … for no apparent reason.” 

Practically speaking, this means families may find themselves accused of wrongdoing (or coerced into quiet settlement) while the processes, evidence and reasoning remain entirely hidden from view.

Worse still, these orders can apply to public bodies such as the OPG itself, insulating its decision-making from public scrutiny. 

Innocent Relatives Cast as Perpetrators

At the heart of the concern is that relatives, often the person closest to the vulnerable individual and already facing huge financial and emotional burdens are suspected, investigated or side-lined with minimal transparency. While specific names and dates are understandably anonymised, the patterns are evident:

Families recount being labelled as “concerned with their own interests” by the OPG or Court, despite no credible evidence of abuse.

The stress on relatives is profound. One family’s voice:

“We are all receiving medical help for the stress … it’s not stress due to my father’s illness – but due to all of this!” 

Although I could not locate a publicly-reported case in which a relative was definitively found innocent yet publicly cleared (owing to anonymity orders), the fact that the narrative of “accused relative” can proceed behind closed doors is deeply troubling. The system allows for a relative to be treated as a suspect, with the game largely hidden from view.

The Power Imbalance: Vulnerable Person vs State Apparatus

The vulnerable individual is meant to be the system’s focus. Yet the apparatus—OPG investigations, deputies, Court proceedings—can shift the locus of control away from the person and their trusted circle into a framework where state-appointed officials and judicial fiat dominate.

Some commentators argue the Court of Protection “institutionalises inequality … allows untested and hearsay evidence, restricts participation and disclosure” and thus risks breaching fair-trial standards. 

When trust and cooperation of relatives is replaced by suspicion and exclusion, the very aim of safeguarding may be undermined. Families describe how they are “never told what the goal-posts are”, “constantly moved on”, and prevented from simply being a family with their loved one. 

When the “Protector” Becomes the Gatekeeper

The OPG’s formal account of its investigative powers states that although around 2,800 investigations may be opened each year, “in most cases we find that there is no case to answer”. 

Yet this doesn’t mitigate the impact on those lives on which such investigations are launched. The act of being under investigation, being treated as a potential perpetrator, often sealed behind ‘confidentiality’, can itself be destructive: emotionally, financially and socially.

The official complaints procedure of the OPG emphasises responsiveness—aiming to reply within 10 working days, offering apologies and redress for proven mistakes.  But that only works after the damage is done. The system does little to ensuretransparency before or during the process which has the potential to pulverise a family’s trust and life.

Why It Matters

Transparency is not optional when the state effectively takes over personal decision-making, finances and care of those lacking capacity. Without clear oversight, power becomes unaccountable.

Relatives must not be collateral damage in protection systems. When a relative is treated as suspect, the family unit is fractured, and the very support the vulnerable person needs is compromised.

Public confidence in the guardianship framework demands more than good outcomes: it demands visible, understandable, and fair processes. The current veil of secrecy undermines deeper trust.

What Could Change

Defaults to openness: The CoP should adopt publication of hearings or summaries by default unless there is a compelling privacy reason—not the other way around.

Independent oversight: A body independent from the OPG should audit cases where relatives were investigated but cleared, ensuring learning and accountability.

Clearer pathways for families: When families are told they are “being investigated”, they should have the right to know the allegations, the evidence, and to respond—rather than being passive subjects.

Redress for families harmed by process: If a relative has been wrongly treated as a perpetrator, there should be accessible mechanisms for apology, compensation and restoration of name.

In Conclusion

The Office of the Public Guardian was established to protect those who cannot protect themselves. Yet somewhere along the way, the balance of power has shifted. Instead of championing the rights of the vulnerable, the system risks treating their trusted relatives as adversaries and cloaking its actions in near-total secrecy.

For a democracy that values dignity, justice and openness, this cannot stand. The very people who ought to be protected—the most vulnerable—deserve more than a system that operates behind locked doors. Families deserve more than the fear of being branded perpetrators without ever seeing the case against them.

The guardianship framework must be reformed not just in form but in spirit. And the public, including those whose voices are quieted by gagging orders must hold it to account.

A delayed discharge case is when a patient is medically ready to leave a hospital but remains there for non-medical reasons. The delay can be caused by factors like a lack of available social care, insufficient community care packages, or issues with the hospital’s own processes. These delays are a major concern as they reduce hospital bed capacity, potentially leading to poorer patient outcomes and increased healthcare costs. 

Delayed discharges: why it’s hard to say how many are due to social care capacity

Authors

Here’s a multiple-choice quiz. What percentage of delayed discharges from hospital are caused by lack of adult social care capacity? Is it:

a) Most of them

b) 50%

c) 12%

d) There’s no way of knowing for certain.

The answer is d): we just don’t know. You get half a point if you said c) because 12% is the most we can definitely attribute to lack of social care capacity from the publicly available data. However, you’d be forgiven for thinking it was b) or even a) if you simply read the media coverage. In December, the Royal College of Nursing was quoted as saying that there was ‘barely a spare bed’ left in NHS hospitals due to a lack of capacity in social care; while in January, the NHS Confederation was reported as saying that 20% of NHS bed capacity was taken up by patients who were only there because they ‘cannot get a suitable care package’.

“Yet we don’t know the number – because, with the best of intentions, we chose to stop asking.”

Yet we don’t know the number – because, with the best of intentions, we chose to stop asking. In 2020, NHS England stopped separating out reasons for delay between health and social care. The reasoning, based on discussions with health and care organisations, was that delays were often complex, and instead of allocating them to one or other partner, systems should take responsibility, rather than individual sectors.

The most recent data recording, introduced in May 2024, requires discharge hubs (or sometimes wards) to classify the causes of delay into one of five categories:

  1. Hospital process (issues within the hospital’s control, such as medication or transport)
  2. Wellbeing concerns (issues outside the hospital’s control, for example where a family has doubts about a patient’s readiness for discharge)
  3. Care transfer hub process (most commonly where the patient’s destination has not yet been decided)
  4. Interface process (typically where transfer plans are underway but have not yet been completed)
  5. Capacity (where the service needed by the patient is not yet available).

Except for hospital process, all these categories include delays that are due to both the NHS and social care. For patients with stays of at least 14 days (the only publicly available measure), on average 9,309 people were delayed each day in March 2025. Of these, 3,203 delays were ascribed to ‘capacity’, followed by interface process (2,639), hospital process (1,754), care transfer hub process (1,200) and wellbeing concerns (514).

If we focus on those 3,203 capacity delays – because lack of social care capacity is often cited as a key cause of delayed discharges – the single largest reason (966 people delayed) is lack of ‘bed-based rehabilitation, reablement or recovery services’.

https://www.landmarkchambers.co.uk/news-and-cases/blog/health-and-social-care-law/delayed-transfer-of-care-leads-to-100k-legal-bill-for-an-icb

This covers a wide range of health and care services, some of which are commissioned by NHS trusts, some by local authorities and some jointly. Even discharge hubs would not be able to allocate them to ‘the NHS’ or ‘social care’. The same applies to ‘home-based rehabilitation, reablement or recovery services’ (502 people delayed), which again cannot be split neatly into social care or NHS.

In fact, only three of the sub-categories – lack of home-based social care services (257), lack of residential or nursing care (762), and people waiting for restart of existing social care services (63) – are solely attributable to social care. But these account for only 34% (1,082) of the 3,203 total ‘capacity’ delays and only 12% of the total 9,309 delayed patients. The real figure for social care delays will be higher because it will include some of the bed-based and home-based rehabilitation and reablement delays but is not counted.

“Yet the NHS and social care are two distinct systems, funded differently, usually commissioned differently and often with different immediate concerns.”

Author:

Into that data vacuum has emerged a range of guesses and estimates, some more authoritative than others. For example, in March NHS England told the House of Commons Health and Social Care Committee that around a fifth of bed days (note that this is a different measure to the publicly available one) lost to delayed discharge ‘are for individuals accessing adult social care packages on discharge’.

In an ideal world, it might not matter. Local systems would be working together to identify problems, avoiding blame and finding joint solutions. Perhaps most are already. Yet the NHS and social care are two distinct systems, funded differently, usually commissioned differently and often with different immediate concerns. On the NHS side, there is intense media and public concern about hospital capacity, A&E waits and ‘corridor care’. On the social care side, there is a longstanding grievance about lack of funding.

In these circumstances, it has sometimes suited both sides for lack of social care capacity to be seen as the key cause of hospital discharge delays. It allows social care to make the case for more money and deflects attention from the NHS causes of delay. This is why the headlines are tolerated, sometimes encouraged.

“It allows social care to make the case for more money and deflects attention from the NHS causes of delay. This is why the headlines are tolerated, sometimes encouraged. ”

Author:

Yet it can still rankle within social care if it is held largely responsible for a problem to which it is, in fact, only a minority contributor. There is a long and inglorious tradition of blaming social care for hospital discharge delays.

There is also irritation about the word ‘capacity’: there is plenty of capacity in care homes, says the sector (occupancy has still not quite returned to pre-pandemic level); the issue is that commissioners (in both the NHS and local authorities) are not sufficiently well organised and are unable or unwilling to pay a fair price for it.

In this difficult environment, avoiding a blame game on hospital discharge was always going to be ambitious. It’s proved to be that – and more. Time to accept reality and publish a credible official estimate of the respective responsibilities for delayed discharge of health and social care.

Further reading